{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:19:45Z","timestamp":1790752785168,"version":"4.1.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["114 024 154"],"award-info":[{"award-number":["114 024 154"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["91 216 021"],"award-info":[{"award-number":["91 216 021"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["777 364"],"award-info":[{"award-number":["777 364"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience & Biobehavioral Reviews"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.neubiorev.2022.104722","type":"journal-article","created":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T11:33:49Z","timestamp":1654688029000},"page":"104722","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Translational validity and methodological underreporting in animal research: A systematic review and meta-analysis of the Fragile X syndrome (Fmr1 KO) rodent model"],"prefix":"10.1016","volume":"139","author":[{"given":"Renate","family":"Kat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Arroyo-Araujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob B.M.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marthe A.","family":"Koopmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sietse F.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martien J.H.","family":"Kas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neubiorev.2022.104722_bib1","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/sj.npp.1300366","article-title":"Behavioral and neurochemical vulnerability during adolescence in mice: Studies with nicotine","volume":"29","author":"Adriani","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neubiorev.2022.104722_bib2","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1023\/A:1026048027397","article-title":"Autistic behavior in young boys with fragile X syndrome","volume":"28","author":"Bailey","year":"1998","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.neubiorev.2022.104722_bib3","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1601-183X.2010.00585.x","article-title":"Male and female Fmr1 knockout mice on C57 albino background exhibit spatial learning and memory impairments","volume":"9","author":"Baker","year":"2010","journal-title":"Genes. Brain Behav."},{"key":"10.1016\/j.neubiorev.2022.104722_bib4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1300\/J006v28n01_06","article-title":"Developmental trajectories and correlates of sensory processing in young boys with fragile X syndrome developmental trajectories and correlates of sensory processing in young boys with fragile X syndrome","volume":"28","author":"Baranek","year":"2009","journal-title":"Phys. Occup. Ther. Pediatr."},{"key":"10.1016\/j.neubiorev.2022.104722_bib5","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1542\/peds.95.5.744","article-title":"Specification of the neurobehavioral phenotype in males with fragile X syndrome","volume":"95","author":"Baumgardner","year":"1995","journal-title":"Pediatrics"},{"key":"10.1016\/j.neubiorev.2022.104722_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2045-5380-1-9","article-title":"Criteria of validity for animal models of psychiatric disorders: focus on anxiety disorders and depression","volume":"1","author":"Belzung","year":"2011","journal-title":"Biol. Mood Anxiety Disord."},{"key":"10.1016\/j.neubiorev.2022.104722_bib7","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1136\/jmg.2008.063701","article-title":"A pilot open label, single dose trial of fenobam in adults with fragile X syndrome","volume":"46","author":"Berry-Kravis","year":"2009","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.neubiorev.2022.104722_bib8","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/d41586-019-01307-2","article-title":"Rein in the four horsemen of irreproducibility","volume":"568","author":"Bishop","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.neubiorev.2022.104722_bib9","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/hmg\/10.16.1693","article-title":"Instability of a (CGG)98 repeat in the Fmr1 promoter","volume":"10","author":"Bontekoe","year":"2001","journal-title":"Hum. Mol. Genet"},{"key":"10.1016\/j.neubiorev.2022.104722_bib10","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.4161\/15384101.2014.989114","article-title":"The GABAA receptor is an FMRP target with therapeutic potential in fragile X syndrome","volume":"14","author":"Braat","year":"2015","journal-title":"Cell Cycle"},{"key":"10.1016\/j.neubiorev.2022.104722_bib11","series-title":"Experimental and quasi-experimental designs for research","author":"Campbell","year":"1963"},{"key":"10.1016\/j.neubiorev.2022.104722_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13052-017-0355-y","article-title":"Fragile X syndrome: a review of clinical and molecular diagnoses","volume":"43","author":"Ciaccio","year":"2017","journal-title":"Ital. J. Pediatr."},{"key":"10.1016\/j.neubiorev.2022.104722_bib13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11689-010-9067-y","article-title":"Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: prevalence and characterization","volume":"3","author":"Cordeiro","year":"2011","journal-title":"J. Neurodev. Disord."},{"key":"10.1016\/j.neubiorev.2022.104722_bib14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.bbr.2014.05.046","article-title":"Behavioral analysis of male and female Fmr1 knockout mice on C57BL\/6 background","volume":"271","author":"Ding","year":"2014","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neubiorev.2022.104722_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-020-0833-4","article-title":"Transcriptome signature analysis repurposes trifluoperazine for the treatment of fragile X syndrome in mouse model","volume":"3","author":"Ding","year":"2020","journal-title":"Commun. Biol."},{"key":"10.1016\/j.neubiorev.2022.104722_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/biology10050433","article-title":"An \u201comic\u201d overview of fragile X syndrome","volume":"10","author":"Dionne","year":"2021","journal-title":"Biology"},{"key":"10.1016\/j.neubiorev.2022.104722_bib17","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"10.1016\/j.neubiorev.2022.104722_bib18","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"Br. Med. J."},{"key":"10.1016\/j.neubiorev.2022.104722_bib19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.gene.2007.02.026","article-title":"Regional FMRP deficits and large repeat expansions into the full mutation range in a new Fragile X premutation mouse model","volume":"395","author":"Entezam","year":"2007","journal-title":"Gene"},{"key":"10.1016\/j.neubiorev.2022.104722_bib20","series-title":"The Mouse in Biomedical Research","first-page":"637","article-title":"Mouse models in aging research","author":"Flurkey","year":"2007"},{"key":"10.1016\/j.neubiorev.2022.104722_bib21","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/sj.mp.4001432","article-title":"Sensorimotor gating abnormalities in young males with fragile X syndrome and Fmr1-knockout mice","volume":"9","author":"Frankland","year":"2004","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neubiorev.2022.104722_bib22","first-page":"1431","article-title":"The laboratory rat: age and body weight matter","volume":"20","author":"Ghasemi","year":"2021","journal-title":"EXCLI J."},{"key":"10.1016\/j.neubiorev.2022.104722_bib23","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ajmg.1320230128","article-title":"An analysis of autism in fifty males with the fragile X syndrome","volume":"23","author":"Hagerman","year":"1986","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.neubiorev.2022.104722_bib24","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1352\/2008.113:427-438","article-title":"Autism profiles of males with fragile X syndrome","volume":"113","author":"Harris","year":"2008","journal-title":"Am. J. Ment. Retard."},{"key":"10.1016\/j.neubiorev.2022.104722_bib25","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1542\/peds.2010-3500","article-title":"Clinical report-health supervision for children with fragile X syndrome","volume":"127","author":"Hersh","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.neubiorev.2022.104722_bib26","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/ajmg.b.30858","article-title":"Prepulse inhibition in fragile X syndrome: Feasibility, reliability, and implications for treatment","volume":"150","author":"Hessl","year":"2009","journal-title":"Am. J. Med. Genet. Part B Neuropsychiatr. Genet."},{"key":"10.1016\/j.neubiorev.2022.104722_bib27","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med."},{"key":"10.1016\/j.neubiorev.2022.104722_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2019.106193","article-title":"A single early-life seizure results in long-term behavioral changes in the adult Fmr1 knockout mouse","volume":"157","author":"Hodges","year":"2019","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neubiorev.2022.104722_bib29","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-14-43","article-title":"SYRCLE\u2019s risk of bias tool for animal studies","volume":"14","author":"Hooijmans","year":"2014","journal-title":"BMC Med. Res. Method."},{"key":"10.1016\/j.neubiorev.2022.104722_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pbio.3001177","article-title":"Epidemiology and reporting characteristics of preclinical systematic reviews","volume":"19","author":"Hunniford","year":"2021","journal-title":"PLoS Biol."},{"key":"10.1016\/j.neubiorev.2022.104722_bib31","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1177\/0962280212461098","article-title":"Obtaining evidence by a single well-powered trial or several modestly powered trials","volume":"25","author":"Inthout","year":"2016","journal-title":"Stat. Methods Med. Res."},{"key":"10.1016\/j.neubiorev.2022.104722_bib32","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s00213-013-3289-0","article-title":"The challenges of clinical trials in fragile X syndrome","volume":"231","author":"Jacquemont","year":"2014","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.neubiorev.2022.104722_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-62509-7","article-title":"A multi-batch design to deliver robust estimates of efficacy and reduce animal use \u2013 a syngeneic tumour case study","volume":"10","author":"Karp","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neubiorev.2022.104722_bib34","doi-asserted-by":"crossref","first-page":"118","DOI":"10.5582\/irdr.2014.01024","article-title":"Modeling fragile X syndrome in the Fmr1 knockout mouse","volume":"3","author":"Kazdoba","year":"2014","journal-title":"Intractable Rare Dis. Res."},{"key":"10.1016\/j.neubiorev.2022.104722_bib35","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1542\/peds.2013-4301","article-title":"Fragile X syndrome: a review of associated medical problems","volume":"134","author":"Kidd","year":"2014","journal-title":"Pediatrics"},{"key":"10.1016\/j.neubiorev.2022.104722_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007824","article-title":"Survey of the quality of experimental design, statistical analysis and reporting of research using animals","volume":"4","author":"Kilkenny","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.neubiorev.2022.104722_bib37","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1365-2788.2008.01135.x","article-title":"A comparative neuropsychological test battery differentiates cognitive signatures of Fragile X and Down syndrome","volume":"53","author":"Kogan","year":"2009","journal-title":"J. Intellect. Disabil. Res"},{"key":"10.1016\/j.neubiorev.2022.104722_bib38","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nature11556","article-title":"A call for transparent reporting to optimize the predictive value of preclinical research","volume":"490","author":"Landis","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.neubiorev.2022.104722_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.61882","article-title":"Defective memory engram reactivation underlies impaired fear memory recall in fragile x syndrome","volume":"9","author":"Li","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.neubiorev.2022.104722_bib40","first-page":"1","article-title":"\u03b1-Asarone ameliorated learning and memory ability in fragile x syndrome model mice via down-regulating p-ERK1\/2 expression","volume":"11","author":"Liao","year":"2018","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.neubiorev.2022.104722_bib41","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.neulet.2009.02.066","article-title":"Dissociation of social and nonsocial anxiety in a mouse model of fragile X syndrome","volume":"454","author":"Liu","year":"2009","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neubiorev.2022.104722_bib42","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1601-183X.2009.00534.x","article-title":"A comparative study of the performance of individuals with fragile X syndrome and Fmr1 knockout mice on Hebb-Williams mazes","volume":"9","author":"MacLeod","year":"2010","journal-title":"Genes, Brain Behav."},{"key":"10.1016\/j.neubiorev.2022.104722_bib43","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.bbr.2018.04.042","article-title":"Modelling fragile X syndrome in the laboratory setting: a behavioral perspective","volume":"350","author":"Melancia","year":"2018","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neubiorev.2022.104722_bib44","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neuron.2012.03.009","article-title":"Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice","volume":"74","author":"Michalon","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.neubiorev.2022.104722_bib45","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.nbd.2005.08.019","article-title":"The generation of a conditional Fmr1 knock out mouse model to study Fmrp function in vivo","volume":"21","author":"Mientjes","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neubiorev.2022.104722_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2040-2392-6-1","article-title":"Antipurinergic therapy corrects the autism-like features in the Fragile X (Fmr1 knockout) mouse model","volume":"6","author":"Naviaux","year":"2015","journal-title":"Mol. Autism"},{"key":"10.1016\/j.neubiorev.2022.104722_bib47","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1177\/0883073817712875","article-title":"Autism symptoms in fragile X syndrome","volume":"32","author":"Niu","year":"2017","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.neubiorev.2022.104722_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"10.1016\/j.neubiorev.2022.104722_bib49","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.neubiorev.2022.104722_bib50","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1037\/a0013047","article-title":"Reversal of sensorimotor gating abnormalities in Fmr1 knockout mice carrying a human Fmr1 transgene","volume":"122","author":"Paylor","year":"2008","journal-title":"Behav. Neurosci."},{"key":"10.1016\/j.neubiorev.2022.104722_bib51","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nrd3439-c1","article-title":"Believe it or not: How much can we rely on published data on potential drug targets?","volume":"10","author":"Prinz","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neubiorev.2022.104722_bib52","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0014-2999(03)01272-X","article-title":"The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review","volume":"463","author":"Prut","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neubiorev.2022.104722_bib53","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.bbr.2015.05.003","article-title":"Endocannabinoid-mediated improvement on a test of aversive memory in a mouse model of fragile X syndrome","volume":"291","author":"Qin","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neubiorev.2022.104722_bib54","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.neubiorev.2020.04.010","article-title":"Perinatal selective serotonin reuptake inhibitor exposure and behavioral outcomes: a systematic review and meta-analyses of animal studies","volume":"114","author":"Ramsteijn","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neubiorev.2022.104722_bib55","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s10803-013-1905-9","article-title":"Eyeblink conditioning: a non-invasive biomarker for neurodevelopmental disorders","volume":"45","author":"Reeb-Sutherland","year":"2015","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.neubiorev.2022.104722_bib56","doi-asserted-by":"crossref","first-page":"11557","DOI":"10.1073\/pnas.0504984102","article-title":"Enriched environment promotes behavioral and morphological recovery in a mouse model for the fragile X syndrome","volume":"102","author":"Restivo","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neubiorev.2022.104722_bib57","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/laban.1330","article-title":"Systematic heterogenization for better reproducibility in animal experimentation","volume":"46","author":"Richter","year":"2017","journal-title":"Lab Anim. (NY)"},{"key":"10.1016\/j.neubiorev.2022.104722_bib58","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0035-16.2016","article-title":"Behavioral phenotype of Fmr1 knock-out mice during active phase in an altered light\/dark cycle","volume":"3","author":"Sar\u00e9","year":"2016","journal-title":"eNeuro"},{"key":"10.1016\/j.neubiorev.2022.104722_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnmol.2017.00452","article-title":"Negative effects of chronic rapamycin treatment on behavior in a mouse model of fragile X syndrome","volume":"10","author":"Sar\u00e9","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.neubiorev.2022.104722_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci9010013","article-title":"Comparative behavioral phenotypes of Fmr1 KO, Fxr2 Het, and Fmr1 KO\/Fxr2 het mice","volume":"9","author":"Sar\u00e9","year":"2019","journal-title":"Brain Sci."},{"key":"10.1016\/j.neubiorev.2022.104722_bib61","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci9010015","article-title":"Executive function in fragile X syndrome: a systematic review","volume":"9","author":"Schmitt","year":"2019","journal-title":"Brain Sci."},{"key":"10.1016\/j.neubiorev.2022.104722_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2013.04.001","article-title":"Brain development in rodents and humans: identifying benchmarks of maturation and vulnerability to injury across species","volume":"106\u2013107","author":"Semple","year":"2013","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neubiorev.2022.104722_bib63","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/jcbfm.2014.28","article-title":"Systematic reviews and meta-analysis of preclinical studies: Why perform them and how to appraise them critically","volume":"34","author":"Sena","year":"2014","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"10.1016\/j.neubiorev.2022.104722_bib64","first-page":"624","article-title":"The laboratory rat: Relating its age with human\u2019s","volume":"4","author":"Sengupta","year":"2013","journal-title":"Int. J. Prev. Med."},{"key":"10.1016\/j.neubiorev.2022.104722_bib65","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1093\/hmg\/ddl121","article-title":"Exaggerated behavioral phenotypes in Fmr1\/Fxr2 double knockout mice reveal a functional genetic interaction between Fragile X-related proteins","volume":"15","author":"Spencer","year":"2006","journal-title":"Hum. Mol. Genet"},{"key":"10.1016\/j.neubiorev.2022.104722_bib66","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fnmol.2019.00051","article-title":"Molecular mechanisms of synaptic dysregulation in fragile X syndrome and autism spectrum disorders","volume":"12","author":"Telias","year":"2019","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.neubiorev.2022.104722_bib67","first-page":"23","article-title":"Fmr1 knockout mice: a model to study fragile X mental retardation","volume":"78","author":"The Dutch-Belgian Fragile X Consortium","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.neubiorev.2022.104722_bib68","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/0092-8674(91)90397-H","article-title":"Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome","volume":"65","author":"Verkerk","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.neubiorev.2022.104722_bib69","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.tips.2016.05.003","article-title":"Reproducibility crisis: are we ignoring reaction norms?","volume":"37","author":"Voelkl","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neubiorev.2022.104722_bib70","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/s41583-020-0313-3","article-title":"Reproducibility of animal research in light of biological variation","volume":"21","author":"Voelkl","year":"2020","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neubiorev.2022.104722_bib71","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.trsl.2020.11.002","article-title":"The effect of macrophage-targeted interventions on blood pressure \u2013 a systematic review and meta-analysis of preclinical studies","volume":"230","author":"Wenstedt","year":"2021","journal-title":"Transl. Res."},{"key":"10.1016\/j.neubiorev.2022.104722_bib72","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00439-002-0723-5","article-title":"Timing of the absence of FMR1 expression in full mutation chorionic villi","volume":"110","author":"Willemsen","year":"2002","journal-title":"Hum. Genet."},{"key":"10.1016\/j.neubiorev.2022.104722_bib73","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/81541","article-title":"Behaviour and the standardization fallacy","volume":"26","author":"Wurbel","year":"2000","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neubiorev.2022.104722_bib74","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s10803-010-1040-9","article-title":"Brief report: Sensorimotor gating in idiopathic autism and autism associated with fragile X syndrome","volume":"41","author":"Yuhas","year":"2011","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.neubiorev.2022.104722_bib75","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/nn.3864","article-title":"Dendritic channelopathies contribute to neocortical and sensory hyperexcitability in Fmr1-\/y mice","volume":"17","author":"Zhang","year":"2014","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neubiorev.2022.104722_bib76","first-page":"9","article-title":"Repeat instability in the fragile x-related disorders: lessons from a mouse model","author":"Zhao","year":"2019","journal-title":"Brain Sci."},{"key":"10.1016\/j.neubiorev.2022.104722_bib77","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1124\/jpet.108.143990","article-title":"Inactivation of the maternal fragile X gene results in sensitization of GABAB receptor function in the offspring","volume":"327","author":"Zupan","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neubiorev.2022.104722_bib78","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/gbb.12298","article-title":"Programming social behavior by the maternal fragile X protein","volume":"15","author":"Zupan","year":"2016","journal-title":"Genes. Brain Behav."},{"key":"10.1016\/j.neubiorev.2022.104722_bib79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.24260","article-title":"Standardized mean differences cause funnel plot distortion in publication bias assessments","volume":"6","author":"Zwetsloot","year":"2017","journal-title":"Elife"}],"container-title":["Neuroscience & Biobehavioral Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763422002111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763422002111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:13:43Z","timestamp":1758968023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149763422002111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":79,"alternative-id":["S0149763422002111"],"URL":"https:\/\/doi.org\/10.1016\/j.neubiorev.2022.104722","relation":{},"ISSN":["0149-7634"],"issn-type":[{"value":"0149-7634","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Translational validity and methodological underreporting in animal research: A systematic review and meta-analysis of the Fragile X syndrome (Fmr1 KO) rodent model","name":"articletitle","label":"Article Title"},{"value":"Neuroscience & Biobehavioral Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neubiorev.2022.104722","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104722"}}